• Explore /
  • Poster
  • / REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).

REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).

Abstract Poster

Authors

null

Tomohiro Matsushima

Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan

Tomohiro Matsushima , Yukiya Narita , Toshihiro Misumi , Yasuhiro Sakamoto , Hiroshi Matsuoka , Hiroaki Tanioka , Takeshi Kawakami , Hiroto Miwa , Hirokazu Shoji , Atsushi Ishiguro , Takanobu Yamada , Sachio Fushida , Kou Miura , Katsunori Shinozaki , Takuro Mizukami , Tomohiro Nishina , Toshikazu Moriwaki , Seiichiro Mitani , Michio Nakamura , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

DOI

10.1200/JCO.2022.40.4_suppl.257

Abstract #

257

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

First Author: Mai Utsumi

First Author: Lorenzo Pilla

First Author: Arvind Dasari

First Author: Yukiya Narita